Related Experiment Video

Updated: Apr 7, 2026

The Lambda Select cII Mutation Detection System
07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

8.5K

In vitro evaluation of cytotoxic and mutagenic activity of avarol

Boris Pejin1,2, Carmine Iodice1, Vesna Kojic3

  • 1a National Research Council of Italy, Institute of Biomolecular Chemistry, CNR-ICB , Pozzuoli-Naples , Italy.

Natural Product Research
|July 17, 2015
PubMed

Insights

Avarol, a sponge compound, shows selective toxicity against colon cancer cells. It is significantly less toxic to normal cells than doxorubicin, suggesting potential for new cancer drug development.

Area of Science:

  • Marine natural products chemistry
  • Cancer biology
  • Drug discovery

Background:

  • Avarol is a secondary metabolite from the Dysidea avara sponge.
  • Natural products are a source of novel therapeutic agents.
  • Understanding avarol's cytotoxicity is crucial for drug development.

Purpose of the Study:

  • To evaluate the in vitro cytotoxicity of avarol against human tumor cell lines.
  • To compare avarol's toxicity to normal cells with a standard chemotherapy drug.
  • To investigate avarol's effect on DNA integrity.

Main Methods:

  • Cytotoxicity screening using MTT assay.
  • Testing against four human tumor cell lines (including HT-29).
  • Assessment of toxicity against normal human fetal lung fibroblast MRC-5 cells.
  • Comet assay to evaluate DNA fragmentation.

Main Results:

  • Avarol demonstrated selective cytotoxicity, primarily affecting HT-29 colon tumor cells.
  • No significant toxicity was observed in normal MRC-5 cells at tested concentrations.
  • Avarol exhibited 588-fold less toxicity towards normal cells compared to doxorubicin.
  • DNA fragmentation was significantly lower with avarol treatment than with doxorubicin.

Conclusions:

  • The avarol scaffold shows promise for developing new nature-inspired cytostatic drugs.
  • Avarol presents a favorable safety profile compared to doxorubicin.
  • Further research into avarol derivatives could lead to novel cancer therapeutics.
Keywords:
Dysidea avaracomet assayhuman tumourssesquiterpenoid hydroquinone

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K
Assays for the Identification of Novel Antivirals against Bluetongue Virus12:02

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

14.7K

Related Concept Videos

In vitro Mutagenesis01:16

In vitro Mutagenesis

5.6K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.7K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
142
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
114
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
538